Acer Therapeutics Stock Price, News & Analysis (NASDAQ:ACER)

Acer Therapeutics trades on the NASDAQ under the ticker symbol "ACER."

Acer Therapeutics Inc (NASDAQ:ACER) announced its earnings results on Tuesday, August, 13th. The biopharmaceutical company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($0.78) by $0.31. View Acer Therapeutics' Earnings History.

Acer Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, November 8th 2019. View Earnings Estimates for Acer Therapeutics.

5 brokers have issued 1-year price targets for Acer Therapeutics' stock. Their predictions range from $9.00 to $48.00. On average, they anticipate Acer Therapeutics' share price to reach $31.00 in the next year. This suggests a possible upside of 756.4% from the stock's current price. View Analyst Price Targets for Acer Therapeutics.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acer Therapeutics in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Acer Therapeutics.

Media headlines about ACER stock have been trending somewhat negative recently, according to InfoTrie. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Acer Therapeutics earned a news impact score of -1.3 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Acer Therapeutics.

Some companies that are related to Acer Therapeutics include Aptinyx (APTX), Eton Pharmaceuticals (ETON), Fortress Biotech (FBIO), Scpharmaceuticals (SCPH), Avadel Pharmaceuticals (AVDL), Correvio Pharma (CORV), Menlo Therapeutics (MNLO), Chembio Diagnostics (CEMI), OASMIA PHARMACE/ADR (OASM), Galmed Pharmaceuticals (GLMD), Relmada Therapeutics (RLMD), Sesen Bio (SESN), Corvus Pharmaceuticals (CRVS), Savara (SVRA) and Processa Pharmaceuticals (PCSA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Acer Therapeutics investors own include Sarepta Therapeutics (SRPT), Synergy Pharmaceuticals (SGYP), DryShips (DRYS), NVIDIA (NVDA), Amarin (AMRN), Cytori Therapeutics (CYTX), Novavax (NVAX), Idera Pharmaceuticals (IDRA), Madrigal Pharmaceuticals (MDGL) and Micron Technology (MU).

Acer Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (3.29%), Vanguard Group Inc. (2.76%), Northern Trust Corp (0.48%), Wedbush Securities Inc. (0.24%), JPMorgan Chase & Co. (0.21%) and Citadel Advisors LLC (0.17%). Company insiders that own Acer Therapeutics stock include Life Science Ventures Vii Tvm and Steve Aselage. View Institutional Ownership Trends for Acer Therapeutics.

ACER stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Wedbush Securities Inc., Citadel Advisors LLC, Vanguard Group Inc., Jane Street Group LLC, Charles Schwab Investment Management Inc., Bank of New York Mellon Corp and Northern Trust Corp. Company insiders that have bought Acer Therapeutics stock in the last two years include Life Science Ventures Vii Tvm and Steve Aselage. View Insider Buying and Selling for Acer Therapeutics.

Shares of ACER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ACER stock can currently be purchased for approximately $3.62.

Acer Therapeutics has a market capitalization of $36.56 million and generates $2.90 million in revenue each year. The biopharmaceutical company earns $-21,280,000.00 in net income (profit) each year or ($2.49) on an earnings per share basis. Acer Therapeutics employs 23 workers across the globe.View Additional Information About Acer Therapeutics.

The official website for Acer Therapeutics is http://www.acertx.com/.

Acer Therapeutics' mailing address is 300 WASHINGTON STREET SUITE 351, NEWTON MA, 02458. The biopharmaceutical company can be reached via phone at 844-902-6100 or via email at [email protected]